Novel Anti-CD40L Antibody Slows New Brain Lesions in Relapsing MS

(MedPage Today) -- Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed. At week 12, the adjusted...
Source: MedPage Today Neurology - Category: Neurology Source Type: news